IL-6 signalling in patients with acute ST-elevation myocardial infarction.
Cytokines of the IL-6 family have been related to infarct size and prognosis in patients with myocardial infarction. The aims of the present study were to elucidate possible associations between myocardial necrosis and left ventricular impairment and members of the IL-6 transsignalling system including soluble (s) IL-6R and (s) glycoprotein 130 (sgp130) in patients with ST-elevation myocardial infarction (STEMI) treated with primary PCI. In blood samples from 1028 STEMI patients, collected in-hosptial, we found significant correlations between peak TnT and IL-6 and CRP (p < 0.001, all) and between IL-6 and CRP and LV ejection fraction and NT-proBNP (p < 0.001, all). On the contrary, no significant associations were found between peak TnT and sgp130 or sIL-6R. Furthermore sgp130 was significantly elevated in diabetic patients and also associated with the glucometabolic state. In conclusion, circulating levels of IL-6 and CRP, but not the soluble forms of the receptor (sIL-6R) or the receptor signalling subunit (sgp130) were associated with the extent of myocardial necrosis. The biological importance of the IL-6/gp130-mediated signalling pathways in patients with acute myocardial infarction and dysglycemia should be further elucidated.
Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Faculty of Medicine, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Vibeke N
VN
Ritschel
Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Faculty of Medicine, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Ingebjørg
I
Seljeflot
Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Faculty of Medicine, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Harald
H
Arnesen
Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Sigrun
S
Halvorsen
3rd Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital, 1160 Vienna, Austria.
Thomas
T
Weiss
Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Jan
J
Eritsland
Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Department of Cardiology, Oslo University Hospital, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway ; Center of Heart Failure Research, University of Oslo, Ullevål, Kirkeveien 166, N-0450 Oslo, Norway.
Geir Ø
GØ
Andersen
IL-6; LVEF, left ventricular ejection fraction; Myocardial necrosis; PCI, percutaneous coronary intervention; ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; sIL-6R; sIL-6R, soluble interleukin -6 receptor; sgp130; sgp130, soluble glycoprotein 130